Myeloproliferative neoplasms (MPNs) are rare cancers and include diseases of the blood and bone marrow. MPNs involve dysregulation at the multipotent hematopoietic stem cell (CD34). MPNs occur when the bone marrow produces too many red blood cells, platelets, or certain white blood cells. The primary subtypes include myelofibrosis, polycythemia vera, and essential thrombocythemia.

Prithviraj Bose, MDMyelofibrosis | February 29, 2024
Myelofibrosis, a rare blood cancer, affects four to six per 100,000 individuals in the United States.
View More
Patrick DalyMyelofibrosis | February 29, 2024
An international working group collaborating with the EBMT and ELN updated the 2015 guidelines for HSCT in myelofibrosis.
Melissa BadamoMyelofibrosis | February 28, 2024
Ruxolitinib plus pelabresib was well tolerated and improved spleen and symptom burden in patients with myelofibrosis.
Keightley AmenMyelofibrosis | February 26, 2024
Parsaclisib plus ruxolitinib can improve symptoms and spleen volume in certain patients with myelofibrosis.
Blood Cancer TalksAcute Myeloid Leukemia | February 13, 2024
Dr. Patel and the hosts discuss the TRANSFORM-1 study, MANIFEST-2, AUGMENT-101, and more.
Sanjay Patel, MDVideo Insights | January 19, 2024
Sanjay Patel, MD, discusses a study on spatial mapping of human hematopoiesis using bone marrow tissue.
Claire Harrison, MD, FRCP, FRCPathMyelofibrosis | February 29, 2024
FREEDOM2 is a phase III study comparing fedratinib with best available therapy as a second-line treatment for myelofibrosis.
Leah SherwoodMyeloproliferative Neoplasms | December 13, 2023
“Among the high-risk splicing mutations, SRSF2 has the worst prognostic role,” Dr. Braish and colleagues wrote.
Michael Grunwald, MDMyeloproliferative Neoplasms | December 14, 2023
The REVEAL study identified five risk factors, including leukocytosis, duration of time with PV, and more.
Patrick DalyMyeloproliferative Neoplasms | December 13, 2023
The treatment led to reduced hepcidin levels when used alone or in combination with ruxolitinib.
Sangeetha Venugopal, MDMyelofibrosis | December 13, 2023
Venugopal highlights myelofibrosis research at ASH 2023.
Andrew Kuykendall, MDPolycythemia Vera | December 13, 2023
Real-world databases lent insight into how often patients with PV experience thromboembolic events.
Haifa Kathrin Al-Ali, MDMyelofibrosis | December 13, 2023
Dr. Al-Ali covers data on combined BET and JAK inhibition for patients with myelofibrosis presented at the 2023 ASH Meeting.
Benjamin Rolles, MDMyeloproliferative Neoplasms | December 13, 2023
Worse survival in single-hit TP53 patients was mainly driven by bone marrow fibrosis.
Melissa BadamoMyelofibrosis | December 11, 2023
SRSF2 and SF3B1 were the most common splicing mutations, followed by U2AF1 and ZRSR2.
Emily HayesPolycythemia Vera | December 11, 2023
Knowing who is at high risk in the near term could make it easier to conduct trials of anti-thrombotic therapies.
Emily HayesPolycythemia Vera | December 13, 2023
Developed by Protagonist Therapeutics, rusfertide is a novel injectable synthetic mimetic of the natural hormone hepcidin.
Nico Gagelmann, MDMyelofibrosis | December 12, 2023
CALR and MPL mutations, which are associated with better outcomes, showed earlier mutation clearance than JAK2.
Blood Cancers Today Staff WritersPolycythemia Vera | February 2, 2024
The retrospective study used data on 105 million U.S. patients with linked medical and prescription claims from 2007 to 2019.
Emily HayesMyelofibrosis | December 13, 2023
Mass spectrometry–based proteomics were used to learn more about how MKs drive bone marrow fibrosis.
Emily HayesMyelofibrosis | December 13, 2023
Prevalence of symptoms was assessed with the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
Emily HayesMyelofibrosis | December 13, 2023
The retrospective study evaluated if pacritinib increased PLT counts in the phase III PERSIST-2 and phase II PAC203 studies.
Melissa BadamoMyeloproliferative Neoplasms | December 13, 2023
Tasquinimod inhibited interaction of A9, a protein associated with poor prognosis.
Melissa BadamoMyeloproliferative Neoplasms | December 13, 2023
DT2216 alone was effective, but exhibited a slightly greater cell viability reduction when combined with other therapies.
Blood Cancers Today Staff WritersMyelofibrosis | December 13, 2023
Responses in hemoglobin, white blood cell, and platelet were 75%, 82%, and 74%, respectively, at 24 weeks.
Blood Cancers Today Staff WritersMyelofibrosis | December 13, 2023
Multivariable modeling showed a notable reduction in the risk of GVHD or relapse in the ATG group.
Blood Cancers Today Staff WritersMyelofibrosis | December 8, 2023
Hemoglobin and platelets are correlated with OS, while mutations in ASXL1, EZH2, IDH1/2, U2AF1, and SRSF2 are not.
Patrick DalyPolycythemia Vera | December 13, 2023
Rusfertide quickly induced hematocrit control and maintained improved levels over time in patients with polycythemia vera.
Blood Cancers Today Staff WritersMyeloproliferative Neoplasms | December 13, 2023
Subjectivity of morphological assessment and overlapping pathological features of subtypes can hamper accurate MPN diagnosis.
Blood Cancers Today Staff WritersMyeloproliferative Neoplasms | December 7, 2023
Bomedemstat is an oral lysine-specific demethylase-1 (LSD1) inhibitor clinically active in patients with MPNs.
Emily HayesMyeloproliferative Neoplasms | December 13, 2023
The model could be helpful in understanding fibrotic progression in JAK2V617F mutation–positive MPNs.
Patrick DalyMyelofibrosis | December 13, 2023
The study aimed to address “a substantial unmet need for therapies that alter disease trajectory" in patients with MF.
Blood Cancers Today Staff WritersMyelofibrosis | February 2, 2024
Ruben Mesa, MD, discussed the results at the 65th ASH Annual Meeting and Exposition.
Blood Cancers Today Staff WritersMyeloproliferative Neoplasms | December 13, 2023
Researchers analyzed PV patients allocated to the ropeginterferon alfa-2b arm of the PROUD-PV/CONTINUATION-PV studies.
Blood Cancers Today Staff WritersMyelofibrosis | December 13, 2023
The use of combination therapies including XPO1 inhibitor selinexor is a potentially effective therapeutic strategy in MF.
Patrick DalyMyeloproliferative Neoplasms | December 6, 2023
This is just one finding from a longitudinal analysis of phase III data from the SIMPLIFY-1 and MOMENTUM trials.
Blood Cancers Today Staff WritersMyeloproliferative Neoplasms | December 13, 2023
Review more from the post-hoc time-dependent analysis of the phase III Simplify-1, Simplify-2, and MOMENTUM trials.
Melissa BadamoMyelofibrosis | November 30, 2023
Led by Dr. Lindsay Rein, the goal of the phase I/II trial was to evaluate the safety and efficacy of TP-3654.
Melissa BadamoMyelofibrosis | December 1, 2023
The multicenter trial studied genetic mutations across three cohorts.
Melissa BadamoPolycythemia Vera | November 28, 2023
CR rates were comparable in both treatment groups, but OS was superior in the ruxolitinib group.
Melissa BadamoMyelofibrosis | November 17, 2023
Researchers also observed potential disease modification via rapid stabilization of platelets and stable hemoglobin levels.
Patrick DalyMyelofibrosis | November 16, 2023
There were no significant differences in response rates with pegylated interferon-alpha versus hydroxyurea in MPN treatment.
Melissa BadamoMyelofibrosis | November 16, 2023
The trial is based on “compelling data” from arm III of the ongoing phase II MANIFEST study.
Patrick DalyMyeloproliferative Neoplasms | November 7, 2023
Primary myelofibrosis developed secondary neoplasms earlier and at higher rates versus other myeloproliferative neoplasms.
Patrick DalyMyeloproliferative Neoplasms | November 7, 2023
Essential thrombocythemia with CALR mutations had a higher risk of progression to myelofibrosis compared with JAK2 mutations.
Patrick DalyMyeloproliferative Neoplasms | November 7, 2023
A deep learning-based pathomics approach had potential in estimating bone marrow cellularity in patients with MPNs.
Patrick DalyMyeloproliferative Neoplasms | November 7, 2023
MPNs were not the primary cause of strokes in veterans, though researchers found they were strongly associated.
Patrick DalyMyeloproliferative Neoplasms | November 7, 2023
Patients with polycythemia vera developed secondary malignancies at a higher rate versus other myeloproliferative neoplasms.
Melissa BadamoMyelofibrosis | October 13, 2023
82.5% of MF patients experienced rapid significant decreases in palpable spleen size after two months of ruxolitinib therapy.
Melissa BadamoMyelofibrosis | February 8, 2024
The median duration of therapy is around three years in patients with intermediate or high-risk MF.
Latest News

February 29, 2024